Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).Michael Wang, Patrick M. Reagan, André Goy et al.|Journal of Clinical Oncology|2021Cited by 10